An update on 'progression promoters' in renal diseases

Journal of the National Medical Association

Volumn 95, Issue 1, 2003, Pages 30-42

  Alebiosu, C O ^a  

^a Dugbe General Post Office   (Nigeria)

Author keywords

Intervention strategy; Mechanisms; Progression; Renal disease

Indexed keywords

BLOOD PRESSURE REGULATION; CHROMOSOME 1Q; CIGARETTE SMOKING; DIETARY INTAKE; DISEASE COURSE; DYSLIPIDEMIA; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY INJURY; LONG TERM EXPOSURE; LOW BIRTH WEIGHT; PRIORITY JOURNAL; PROTEIN INTAKE; PROTEINURIA; REVIEW; THYROID FUNCTION; CHRONIC KIDNEY FAILURE; HYPERTENSION; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK FACTOR;

ANGIOTENSIN II;

ANGIOTENSIN II; DISEASE PROGRESSION; HUMANS; HYPERTENSION; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; RISK FACTORS;

EID: 0037264412     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (97)

1. US Renal Data System. USRDS 1991 Annual Data Report. Bethseda, MD: National Institute of Diabetes and Digestive and Kidney diseases, National Institutes of Health; August 1991.
2. Klahr S, Schreiner G and Ichikawa I. The progression of renal disease. New England Journal of Medicine. 1988; 318: 1657-1666.
3. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, Shulman NB and Stamler J. Blood pressure and end-stage renal disease in men. New England Journal of Medicine. 1996; 334: 13-18.
4. Fogo AB. Glomerular hypertension, abnormal glomerular growth and progression of renal diseases. Kidney International. 2000; 57: 515-521
5. Campese VM. Neurogenic factors and hypertension in renal disease. Kidney International. 2000; 57: 52-56.
6. Schalckamp MADH, Schalekamp-Kuyken MPA, Dmoor-Fruytier M, Meininger T, Vaandrager-Kranenburg DJ, and Birkenhager WH. Interrelationship between blood pressure, renin, renin substrate and blood, in terminal renal failure. Clin. Sci. Mol. Med. 1973; 45: 417-428.
7. Converse RL, Jacobsen TN, Toto RD, Tost CMT, Cosentino F, Fouad-Tarazi F, and Victor RG. Sympathetic over activity in patients with CRF. New England Journal of Medicine. 1992; 327: 1912-1918.
8. Moorhead JF, Chan MK, eL-Nahas T. Lipid nephrotoxicity in chronic progressive glomerular and tubulointerstitial disease. Lancet. 1982; 2: 1309-1311.
9. Linda FF, Trevor JO, and Bertram LK. Effect of lipid reduction on the progression of renal disease: a meta analysis. Kidney International. 2001; 59: 260-269.
10. Manttari M, Tiula E, Alikoski T, Manninen V. Effects of hypertension and dyslipidaemia on the decline in renal function. Hypertension. 1995; 26: 670-676.
11. Wheeler DC, and Bernard DB. Lipid abnormalities in the nephrotic syndrome - causes, consequences, and treatment. Am J. Kidney Dis. 1994; 23: 331-346.
12. Keane WF. The role of lipids in renal disease: Future challenges. Kidney International. 2000; 57: 527-531.
13. Muntner P, Coresh J, Smith JC, Eckfeldt J, and Klag MJ. Plasma lipids and risk of developing renal dysfuntion: The Atherosclerosis Risk in Communities Study. Kidney International. 2000; 58: 293-301.
14. Washio M, Okuda S, Ikedia M, Hirakata H, Nanishi F, Onoyama K, Yoshimura T, Fujishima M. Hypercholesterolaemia and the progression of the renal dysfunction in CRF patients. J Epidemiol. 1996; 6: 172-177.
15. Samuelsson O, Mulec H, Knight-Gibson C, Attman PO, Kron B, Larsson R, Weiss L, Wedel H and Alaupovic P. Lip[roprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant. 1997; 12: 1908-1915.
16. Samuelsson O, Aurell M, Knight-Gibson C, Alaupovic P. and Attman PO. Apolipoprotein-B containing lipoproteins and the progression of renal insufficiency. Nephron. 1993; 63: 279-285.
17. Yang WQ, Song NG, Ying SS, Liang HQ, Zhang WJ, Wei MJ and Wu KF. Serum Lipid concentrations correlate with the progression of chronic renal failure. Clin. Lab. Sci. 1999; 12: 104-108.
18. Samuelsson O, Attman PO, Knight-Gibson C, Larsson R, Mulec H, Wedel H, Weiss L, and Alaupovic P. Complex Apolipoprotein-B containing lipoprotein particles are associated with a higher rate of progression of human chronic renal insufficiency. J Am Soc Nephrol. 1998; 9: 1482-1488.
19. Kasiske B, O'Donnell M, Garvis W and Keane WF. Pharmacologic treatment of hyperlipidaemia reduces glomerular injury in rat 5/6 nephrectomy model of CRF. Circ Res. 1988; 62: 367-374.
20. Kasiske B, O'Donnell M, Cleary M and Keane WF. Treatment of hyperlipidaemia reduces glomerular injury in obese Zucker rats. Kidney Int. 1988; 33: 667-672.
21. Stenvinkel P, Alverstand A and Bergstrom J. Factors influencing progression in patients with chronic renal failure. J Intern. Med, 1989, 226: 183-188.
22. Jovanovic DB and Djukanovic LD. Analysis of factors influencing chronic renal failure progression. Renal Failure. 1999; 21: 177-187.
23. Locatelli F, Lucia DV, Simeone A, Paulo M and Flavia T. The role of underlying nephropathy in the progression of renal disease. Kidney Intern. 2000; 57: 549-555.
24. Maschio G, Alberti D, Janin G, Locatelli F, Mann JFE, Motolese M, Ponti celli C, and Zucchelli P. The angiotensin converting - Enzyme inhibition in progressive renal insufficiency (AIPRI). New Engl J Medicine. 1996, 334: 939-845.
25. Locatelli F, Alberti D, Graziani G, Buccianti G, Redaelli B, and Giangrande F. Northern Italian Cooperative study group (NIC). Lancet. 1991; 337: 1299-1304.
26. Hunsicker LG, Adler S, Cagginla A, England BK, and Greene T. The modification of diet in renal disease study group. Kidney Intern. 1997; 51: 1908-1919.
27. Jungers P, Hannnedouche T, Hakura Y, Albouze G, Descams-Latscha B, and Man NK. Progression rate- to end-stage renal failure in non-diabetic kidney disease: a multivariate analysis of determinant factors. Nephrol Dial Transplant. 1995; 10: 1353-1360.
28. Maroni BJ and Mitch WE. Role of nutrition in prevention of the progression of renal disease. Ann Rev Nutr. 1997; 17: 43-455.
29. Chanutin A and Ludewig S. Experimental renal insufficiency produced by partial nephrectomy. V. Diets containing whole dried meat. Arch Int Med. 1936; 58: 60-80.
30. Hostetter TH, Olson JL, Rennke HG, Venkatachlam MA and Brenner BM. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Ann J physiol. 1981; 241: F85-F93.
31. Rosenberg ME, Chmielewski D and Hostetter TH. Effect of dietary protein on rat renin and angiotensinogen expression. J Clin Invest. 1990; 85: 1144-1149.
32. Remuzzi G, Ruggenenti P, and Benigni A. Understanding the nature of renal disease progression. Kidney Int. 1997; 51: 2-15.
33. Walser M, Mitch E, Maroni BJ and Kopple JD. Should protein be restricted in predialysis patients? Kidney Intern. 1999; 55: 771-777.
34. Levey AS, Greene T, Beck GJ, Caggiula A, Kusek J, Hunsicker LG, and Klahrs. Dietary protein restriction and the progression of chronic renal disease: What have all the results of the MDRD study shown? J Ann Soc Nephrol. 1999; 10: 2426-2439.
35. De Jong PE, Navis GJ, and de Zeeuw D. The next step in renoprotection. titrating for proteinuria. Lancet. 1999; 354: 352-353.
36. Wapstra FH, Navis GJ, de Jong PE, and de Zeeuw D. Short-term and long-term antiproteinuric response to inhibition of renin-angiotensin axis in patients with non-diabetic renal disease; prediction of GFR decline. Exp Nephrol. 1996; 4(Suppl II): 47-52.
37. Orth SR, RitzE and Schrier RW. Renal risks of smoking. Kidney Int. 1997; 51: 169-1677.
38. Olivarius NF, Andreasen AH, Keiding N, and Mogensen CE. Epidemiology of renal involvement in newly diagnosed middle-aged and elderly diabetic patients: Cross sectional data from the population-based study, Diabetes Care in General Practice (Denmark). Diabetologia. 1993; 36: 1007-1016.
39. Chapman AB, Johnson AM, Gabow PA, and Schrier RW. Overt Proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 1994, 5: 1349-1354.
40. Hebert LE, Wilmer WA, Falkenhan ME, Ladson-Wofford SE, Nahman NS and Rovin BH. Renoprotection: one or many therapies? Kidney Intern. 2001; 59: 1211-1226.
41. Baggio B, BudaKovic A and Gambaro G. Cardiovascular risk factors, smoking and kidney function. Nephrol Dial Transplant. 1998; 13(suppl 7): 2-5.
42. Gambaro G, Verlato F, BudaKovic A, Casara D, Saladini G, DelPrete D, Bertaglia, Masiero M, Checchetto O, and Baggio B. Renal impairment in chronic cigarette smokers. J Am Soc Nephrol. 1998; 9: 562-567.
43. Halimi JM, Girandeau B, Vol S, Caces E, Nivet H, Lebranchu Y, and Tichet J. Effects of current smoking and smoking discontinuation on renal function and proteinuria in the general population. Kidney Intern. 2000; 58: 1285-1292.
44. Hovind P, Rossing P, Tarnow L, Smidt UM, and Parving HH. Progression of diabetic nephropathy. Kidney Intern. 2001; 59: 702-709.
45. Ritz E and Stefanski A. Type II diabetic nephropathy. Am J Kidney Dis. 1996; 27: 167-194.
46. The Diabetic Control and Complications Research Group. The effects of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Eng J Med. 1993; 329: 977-986.
47. Klahr S and Morisey JJ. The role of vasoactive compounds, growth factors and cytokines in the progression of renal disease. Kidney Intern. 2000; 57(suppl 75): 57-514.
48. Refsum H, Veland P and Nygard O. Homocysteine and cardiovascular disease. Ann Rev Med. 1998; 49: 31-62.
49. Silbriger S and Neugarten J. The impact of gender on the progression of chronic renal disease. Am J Kidney Dis. 1995 25: 515-533.
50. Baker DJ, Bull AR, Osmond C, and Simonds SJ. Fetal and placental size and risk of hypertension in adult life. Brit Med J. 1990; 301: 259-262.
51. Rossing P, Tarnow L, Nielsen FS, Hansen BV, Brenner BM, and Parving HH. Low birth weight. A risk factor for development of diabetic nephropathy? Diabetes. 1995; 44; 1405-1407.
52. Nyengarrd JR and Bendsten TF. Glomerular number and size in relation to age, kidney and body weight in normal man. Anat Rec. 1992, 232: 194-268.
53. Weder AB and Schork NJ. Adaptation, allometry and hypertension. Hypertension. 1994, 24: 145-156.
54. Grim C and Henny LP. High blood pressure in blacks: salt, survival, stress and race, New York, Raven Press, 1995, 208-212.
55. Flegal KM, Carroll MD, Kuczmarski RJ, Johnson CL. Overweight and obesity in the United States: Prevalence and trends. 1960-1994. Int J Obes Relat Metab Discord. 1998; 22: 39-47.
56. Weisinger JR, Kempson RL, Eldridge L, Swenson RS. The nephritic syndrome: A complication of massive obesity. Ann Intern Med. 1974, 81 440-447.
57. Kambham N, Markowitz GS, Valeri AM, Lin J, and D'Agati VD. Obesity-related glomerulopathy: An emerging epidemic. 2001; 59; 1498-1509.
58. Maddox DA, Alavi FK, Silbernick EM, Zawada ET Jr. Protective effects of a soy diet in preventing obesity-linked renal disease. Kidney Intern. 2002; 61: 96-104.
59. Reaven, GM. Role of insulin resistance in human disease. Banting Lecture. Diabetes. 1998; 37: 1595-1607.
60. Pavloic M, Haeberle U, et al. Angiotensin I-converting enzyme-gene-polymorphism: relationship to albumin excretion and blood pressure in paediatric patients with type I diabetic mellitus. Exp Clin Endocrinol Diabetes. 1997; 105: 248-253.
61. Viswanathan V, Zhu Y, Bala K, Dunn S, Snehalatha C, Ramachandran A, Jayaraman M, and Sharma K. Association between ACE gene polymorphism and diabetic nephropathy in South Indian patients. J Pancreas (Online). 2001; 2: 83-87.
62. Cohn HD, Shobat T, Yahav M, Ilan T, Rechavi G, King L and Shohat M. A locus for an autosomal dominant form of progressive renal failure and hypertension at chromosome 1q21. American J of Human Genetics. 2000; 67: 647-651.
63. Ja-Liang Lin, Huei-Huang Ho and Chun-Chen Yu. Chelation therapy for patients with elevated body lead burden and progressive renal insufficiency-A randomized, controlled Trial. Annals of Internal Medicine. 1999: 13; 7-13.
64. Brenner BM, Meyer TV and Hostetter TH. Dietary protein intake and progressive nature of kidney disease: The role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation and intrinsic renal disease. N Engl J Med. 1982; 307: 652-659.
65. Hebert L, Cody R, Slivka A, and Sedmak D: Hypertension-induced kidney, heart and central nervous system disease, diagnosis and management of renal disease and hypertension. Durham, Carolina Medical Press, 1994.
66. Riser B, Cortes P and Zhao X. Intraglomerular pressure and mesangial stretching stimulate extracellular matrix formulation in the rat. J. Clin Invest. 1992; 90: 1932-1943.
67. Hebert L, Bain R and Verme D. Remission of nephrotic range proteinuria in type 1 diabetes. Kidney Intern. 1994; 46: 1688-1693.
68. Hebert L, Kusek J and Greene T. Effects of blood pressure control on progressive renal disease in blacks and whites. Hypertension. 1997, 30: 428-435.
69. He J and Whelton PK. Elevated systolic pressure as a risk factor for cardiovascular and renal disease. J Hypertens. 1999; 17(suppl 2); S7-S13.
70. Oda H and Keane W. Recent advances in statins and the kidney. Kidney Intern. 1999; 56(suppl): S2-S5.
71. Keane WF, O'Donell MP, Kasiske BL, and Kim Y. Oxidative modification of low-density lipoprotein by mesangial cells. J Am Soc Nephrol. 1993; 4: 187-194.
72. Nairk, Pabaico R and Truglia J. Mechanism of glomerular hyperfiltration after a protein meal in humans: Role of hormones and amino acids. Diabetes Care. 1994; 17: 711-7115.
73. Ogrodowski J, Hebert L and Sedmak D. Measurement of SC5b-9 in urine in patients with the nephrotic syndrome. Kidney Intern. 1991, 40: 1141-1147.
74. Nomura A, Morita Y and Maruyama S. Role of complement in acute tubulointerstitial injury of rats with aminonucleoside nephrosis. Am J Pathol. 1997; 151: 539-547.
75. Goetz FC, Jacobs DR, Chavers B, Roel J, Yelle M, and Sprafka JM. Risk factors for kidney damage in the adult population of Wadena, Minnesota. Am J Epidem. 1997; 145: 91-102.
76. United Kingdom Prospective Diabetes Study: Intensive blood glucose control with sulphonylurea or insulin compared with conventional treatment and the risk of complication in patients with type 2 diabetes. Lancet. 1998; 352: 837-853.
77. Gilbert RE and Coope ME. The tubulointerstitium in progressive diabetic kidney disease: More than an aftermath of glomerular injury? Kidney Intern. 1999, 65: 1627-1637.
78. Dunlop M. Aldose reductase and the role of the polyol pathway in diabetic nephropathy. Kidney Intern. 2000; 58 (suppl 77): S3-S12.
79. Nishikawa T, Edestein D and Brownlee M. The Missing Link; A single unifying mechanism for diabetic complications. Kidney Intern. 2000; 58(supp 77): S26-S30.
80. Brenner B and Taal M. Renoprotective benefits of RAS inhibition. From ACEI to angiotensin II antagonists. Kidney Intern. 2000; 57: 1803-1817.
81. Khambam N, Markowitz GS, Vari AM, Lin J, and D'Agati VD. Obesity-related glomerulopathy: An emerging epidemic. Kidney Intern. 2001; 59; 1498-1509.
82. Keane WF. Lipids and the kidney. Kidney International. 1994; 46 910-920.
83. Joles JA, Kunter U, Janssen U, et al. Early mechanisms of renal injury in hypercholesterolaemic or hypertriglyceridaemic rats. J Am Soc Nephrol. 2000; 11: 669-683.
84. Bos H, Anderson S, Rossing P, Zeeuw DD, Parving HH, Dejong PE, and Naris G. Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy. Kidney Intern. 2000; 57(suppl 75): S32-S37.
85. Joint National Committee for the Detection, Evaluation and Treatment of High Blood Pressure. The 1998 report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med. 1998; 148: 1023-1038.
86. Ritz E, Schomig M and Wagner J. Counteracting progression of renal disease: a look into the future. Kidney Intern. 2000; 75 (suppl. 75): S71-S76.
87. Yusuf S. Sleight P and Progue F. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. New Eng J Med. 2000; 342: 145-153.
88. Tarif N. and Bakris G. Angiotensin II receptor blockade and progression of non-diabetic mediated renal disease. Kidney Int. 1997, 52 (suppl.): 567-570.
89. Bakris G and Williams B. ACE-1 and Calcium antagonists alone or combined: Does the progression of diabetic renal disease differ? J. Hypertens. 1995; 13: 595-5101.
90. Inzucchi S, Maggs D and Spollett G. Efficacy and metabolic effects of metforinin and troglitazone in type II diabetes mellitus. N. Engl. J. Med. 1998; 338: 867-872.
91. Rovin B., Doe N and Tan LC. Monocyte Chemoattractant protein-I levels in patients with glomerular disease. Am J Kidney Dis. 1996; 27: 640-646.
92. Kuriyama S, Tomonari H and Yoshida H. Reversal of anemia by erthropoietin therapy retards the progression of chronic renal failure, especially in non-diabetic patients. Nephron. 1999; 77: 176-185.
93. Touam M, Zingraff J and Jungers P. Effective correction of hyperhomocysteinemia in hemodialysis patients by intravenous folic acid and pyridoxine therapy. Kidney Intern. 1999; 56: 2292-2296.
94. Dickinson JC and Prentice C. Aspirin: Benefit and risk in thromboprophylaxis. Quart J Med. 1998; 91: 523-538.
95. He J, Whelton P and Vu B. Aspirin and risk of heamorrhagic stroke: A Meta-analysis of randomized controlled trials. JAMA. 1998; 280: 1930-1935.
96. Amann K, Rump LC, Simonaviciene A, Oberhauser V, Wessels S, Orth SR, Gross ML, Bielenberg GW, van Kats JP, Ehmke H, Mall G, and Ritz E. Effects of sympathetic inhibition on glomerusclerosis and albuminuria in subtotally nephrectomized rats. J Am Soc Nephrol. In Press.
97. Coggins CH, Breyer LJ, Caggiula AW, Castaldo LS, Klahrs, and Wang SR. Differences between women and men with chronic renal disease. Nephrol Dial Transplant. 1998; 13: 1430-1437.